Romania · Delayed Price · Currency is RON Antibiotice Statistics
Total Valuation
Antibiotice has a market cap or net worth of RON 1.40 billion. The enterprise value is 1.75 billion.
| Market Cap | 1.40B |
| Enterprise Value | 1.75B |
Important Dates
The last earnings date was Monday, August 17, 2026.
| Earnings Date | Aug 17, 2026 |
| Ex-Dividend Date | Oct 15, 2026 |
Share Statistics
Antibiotice has 671.34 million shares outstanding. The number of shares has decreased by -0.03% in one year.
| Current Share Class | 671.34M |
| Shares Outstanding | 671.34M |
| Shares Change (YoY) | -0.03% |
| Shares Change (QoQ) | -0.42% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 0.69% |
| Float | 227.94M |
Valuation Ratios
The trailing PE ratio is 172.46.
| PE Ratio | 172.46 |
| Forward PE | n/a |
| PS Ratio | 2.28 |
| PB Ratio | 1.51 |
| P/TBV Ratio | 1.56 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 15.93 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 215.62 |
| EV / Sales | 2.84 |
| EV / EBITDA | 21.04 |
| EV / EBIT | 66.35 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.25, with a Debt / Equity ratio of 0.38.
| Current Ratio | 1.25 |
| Quick Ratio | 0.78 |
| Debt / Equity | 0.38 |
| Debt / EBITDA | 4.24 |
| Debt / FCF | -3.62 |
| Interest Coverage | 5.22 |
Financial Efficiency
Return on equity (ROE) is 0.87% and return on invested capital (ROIC) is 1.39%.
| Return on Equity (ROE) | 0.87% |
| Return on Assets (ROA) | 1.11% |
| Return on Invested Capital (ROIC) | 1.39% |
| Return on Capital Employed (ROCE) | 2.48% |
| Weighted Average Cost of Capital (WACC) | 4.59% |
| Revenue Per Employee | 455,041 |
| Profits Per Employee | 6,002 |
| Employee Count | 1,356 |
| Asset Turnover | 0.41 |
| Inventory Turnover | 1.19 |
Taxes
In the past 12 months, Antibiotice has paid 4.07 million in taxes.
| Income Tax | 4.07M |
| Effective Tax Rate | 33.34% |
Stock Price Statistics
The stock price has decreased by -15.56% in the last 52 weeks. The beta is 0.23, so Antibiotice's price volatility has been lower than the market average.
| Beta (5Y) | 0.23 |
| 52-Week Price Change | -15.56% |
| 50-Day Moving Average | 2.14 |
| 200-Day Moving Average | 2.17 |
| Relative Strength Index (RSI) | 38.74 |
| Average Volume (20 Days) | 100,756 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Antibiotice had revenue of RON 616.58 million and earned 8.13 million in profits. Earnings per share was 0.01.
| Revenue | 616.58M |
| Gross Profit | 353.67M |
| Operating Income | 26.43M |
| Pretax Income | 12.20M |
| Net Income | 8.13M |
| EBITDA | 83.34M |
| EBIT | 26.43M |
| Earnings Per Share (EPS) | 0.01 |
Balance Sheet
The company has 3.08 million in cash and 353.51 million in debt, with a net cash position of -350.43 million or -0.52 per share.
| Cash & Cash Equivalents | 3.08M |
| Total Debt | 353.51M |
| Net Cash | -350.43M |
| Net Cash Per Share | -0.52 |
| Equity (Book Value) | 930.75M |
| Book Value Per Share | 1.39 |
| Working Capital | 121.56M |
Cash Flow
In the last 12 months, operating cash flow was 88.05 million and capital expenditures -185.69 million, giving a free cash flow of -97.64 million.
| Operating Cash Flow | 88.05M |
| Capital Expenditures | -185.69M |
| Depreciation & Amortization | 56.92M |
| Net Borrowing | 97.79M |
| Free Cash Flow | -97.64M |
| FCF Per Share | -0.15 |
Margins
Gross margin is 57.36%, with operating and profit margins of 4.29% and 1.32%.
| Gross Margin | 57.36% |
| Operating Margin | 4.29% |
| Pretax Margin | 1.98% |
| Profit Margin | 1.32% |
| EBITDA Margin | 13.52% |
| EBIT Margin | 4.29% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.04, which amounts to a dividend yield of 1.70%.
| Dividend Per Share | 0.04 |
| Dividend Yield | 1.70% |
| Dividend Growth (YoY) | 170.72% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 146.72% |
| Buyback Yield | 0.03% |
| Shareholder Yield | 1.73% |
| Earnings Yield | 0.58% |
| FCF Yield | -6.96% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on May 13, 2013. It was a forward split with a ratio of 1.1819213313.
| Last Split Date | May 13, 2013 |
| Split Type | Forward |
| Split Ratio | 1.1819213313 |
Scores
Antibiotice has an Altman Z-Score of 2.63 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.63 |
| Piotroski F-Score | 5 |